Targeting phenylalanine assemblies as a prospective disease-modifying therapy for phenylketonuria
Biophysical Chemistry · 2024-05 · 308 · 107215
DOI: 10.1016/j.bpc.2024.107215 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biophysical Chemistry, 2024-05. Verfasst von Shira Shaham-Niv und 10 weiteren Autor:innen. Beteiligte Einrichtung: The Shmunis School of Biomedicine and Cancer Research, Tel Aviv University, Tel Aviv 6997801, Israel; BLAVATNIK CENTER for Drug Discovery, Tel Aviv U…. Hauptthemen laut MEDLINE: Phenylalanine, Phenylketonurias. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Colton Foundation, Israel Science Foundation, March of Dimes Foundation.
Abstract (Originalsprache)
Phenylketonuria is characterized by the accumulation of phenylalanine, resulting in severe cognitive and neurological disorders if not treated by a remarkably strict diet. There are two approved drugs today, yet both provide only a partial solution. We have previously demonstrated the formation of amyloid-like toxic assemblies by aggregation of phenylalanine, suggesting a new therapeutic target to be further pursued. Moreover, we showed that compounds that halt the formation of these assemblies also prevent their resulting toxicity. Here, we performed high-throughput screening, searching for compounds with inhibitory effects on phenylalanine aggregation. Morin hydrate, one of the most promising hits revealed during the screen, was chosen to be tested in vivo using a phenylketonuria mouse model. Morin hydrate significantly improved cognitive and motor function with a reduction in the number of phenylalanine brain deposits. Moreover, while phenylalanine levels remained high, we observed a recovery in dopaminergic, adrenergic, and neuronal markers. To conclude, the ability of Morin hydrate to halt phenylalanine aggregation without reducing phenylalanine levels implies the toxic role of the phenylalanine assemblies in phenylketonuria and opens new avenues for disease-modifying treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Shmunis School of Biomedicine and Cancer Research, Tel Aviv University, Tel Aviv 6997801, Israel; BLAVATNIK CENTER for Drug Discovery, Tel Aviv University, Tel Aviv 6997801, Israel.
- The Shmunis School of Biomedicine and Cancer Research, Tel Aviv University, Tel Aviv 6997801, Israel.
- BLAVATNIK CENTER for Drug Discovery, Tel Aviv University, Tel Aviv 6997801, Israel.
- Nancy and Stephen Grand Israel National Center for Personalized Medicine, Weizmann Institute of Science, Rehovot 7610001, Israel.
- Department of Oral Biology, The Goldschleger School of Dental Medicine, Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
- The Shmunis School of Biomedicine and Cancer Research, Tel Aviv University, Tel Aviv 6997801, Israel; BLAVATNIK CENTER for Drug Discovery, Tel Aviv University, Tel Aviv 6997801, Israel. Electronic address: EhudGa@tauex.…
Förderung
- Colton Foundation
- Israel Science Foundation
- March of Dimes Foundation
Zitieren
APA
Shaham-Niv, S., Ezra, A., Zaguri, D., Shotan, S. R., Haimov, E., Engel, H., Brider, T., Simhaev, L., Barr, H. M., Adler-Abramovich, L., & Gazit, E. (2024). Targeting phenylalanine assemblies as a prospective disease-modifying therapy for phenylketonuria. Biophysical Chemistry, 308, 107215. https://doi.org/10.1016/j.bpc.2024.107215
Vancouver
Shaham-Niv S, Ezra A, Zaguri D, Shotan SR, Haimov E, Engel H, et al. Targeting phenylalanine assemblies as a prospective disease-modifying therapy for phenylketonuria. Biophysical Chemistry. 2024;308:107215. doi:10.1016/j.bpc.2024.107215
BibTeX
@article{ShahamNiv2024,
author = {Shaham-Niv, Shira and Ezra, Assaf and Zaguri, Dor and Shotan, Stav Roni and Haimov, Elvira and Engel, Hamutal and Brider, Tamara and Simhaev, Luba and Barr, Haim Michael and Adler-Abramovich, Lihi and Gazit, Ehud},
title = {Targeting phenylalanine assemblies as a prospective disease-modifying therapy for phenylketonuria},
journal = {Biophysical Chemistry},
year = {2024},
volume = {308},
pages = {107215},
doi = {10.1016/j.bpc.2024.107215}
}
EUVIMED